Tesaro – Developing Transformative Therapies to Treat Cancer
---
High-Level Overview
Tesaro is an oncology-focused biopharmaceutical company dedicated to developing and commercializing transformative therapies for cancer patients. Founded in 2010, Tesaro specializes in acquiring, developing, and bringing to market innovative drugs that address unmet medical needs in oncology. Its flagship products include Varubi, a treatment for chemotherapy-induced nausea and vomiting, and Zejula, a PARP inhibitor that extends the lives of ovarian cancer patients by preventing tumor recurrence. The company has built a robust pipeline of additional oncology assets, positioning itself as a leader in targeted cancer therapies.
Tesaro serves oncologists and patients by providing safer, more effective treatments that improve outcomes and quality of life. The company has demonstrated strong growth momentum, marked by rapid fundraising, a successful IPO, and strategic in-licensing of promising drug candidates. Its ability to commercialize meaningful therapies and expand its portfolio has made it a standout in the biotech sector.
---
Origin Story
Tesaro was founded in 2010 by Lonnie Moulder and Mary Lynne Hedley, both former executives of MGI Pharma, a specialty biopharmaceutical company acquired by Eisai for $3.9 billion in 2008. Drawing on their experience leading MGI Pharma through significant growth, Moulder and Hedley launched Tesaro with a vision to leverage abandoned or underdeveloped assets from large pharmaceutical companies and transform them into life-changing cancer treatments.
The idea emerged from their recognition that many promising drug candidates were being shelved by big pharma due to shifting priorities or strategic realignments. Tesaro’s strategy was to identify these overlooked assets, acquire them, and accelerate their development. Early traction came quickly: the company secured $60 million in initial funding from New Enterprise Associates (NEA) and its management team, followed by a $101 million venture round and a successful IPO that raised $81 million. These milestones validated Tesaro’s model and set the stage for rapid expansion.
---
Core Differentiators
- Asset Repurposing Strategy: Tesaro specializes in acquiring and revitalizing abandoned or underdeveloped drug candidates from large pharma, reducing R&D risk and accelerating time to market.
- Experienced Leadership: The founding team’s track record at MGI Pharma brought deep industry expertise, credibility, and a proven ability to execute on growth and commercialization.
- Focused Oncology Pipeline: The company’s portfolio is concentrated on high-impact cancer therapies, including PARP inhibitors and supportive care agents, addressing critical unmet needs.
- Strategic In-Licensing: Tesaro has in-licensed key assets such as niraparib (Zejula) from Merck and rolapitant from Schering-Plough, expanding its pipeline with minimal upfront R&D costs.
- Strong Investor Backing: Backed by top-tier venture firms including NEA, Kleiner Perkins, and Venrock, Tesaro has access to capital and strategic guidance.
---
Role in the Broader Tech Landscape
Tesaro is riding the wave of precision medicine and targeted oncology therapies, a trend that has reshaped cancer treatment in the 21st century. The timing of its founding was pivotal—biotech IPOs were scarce after the 2008 financial crisis, and Tesaro’s successful public offering signaled renewed investor confidence in the sector. The company’s model of asset repurposing aligns with broader industry shifts toward efficiency, cost-effective drug development, and patient-centric innovation.
By focusing on oncology, Tesaro is addressing one of healthcare’s most pressing challenges. Its success has influenced the broader ecosystem by demonstrating the viability of “asset rescue” strategies and inspiring other biotechs to explore similar approaches. The company’s growth has also contributed to the revitalization of the biotech IPO market, encouraging investment in innovative, science-driven startups.
---
Quick Take & Future Outlook
Tesaro’s future is poised for continued impact in oncology, with its pipeline of targeted therapies and supportive care agents likely to expand further. The trend toward personalized medicine and the increasing demand for effective cancer treatments will continue to drive demand for Tesaro’s products. As the company evolves, it may explore new therapeutic areas or deepen its focus on combination therapies and biomarker-driven approaches.
Looking ahead, Tesaro’s influence will likely extend beyond its own portfolio, shaping how biotech companies approach drug development and commercialization. Its origin story—rooted in the repurposing of abandoned assets and the vision of experienced leaders—remains a powerful example of how innovation can emerge from overlooked opportunities. Tesaro’s journey underscores the potential for transformative change in healthcare, proving that even the most challenging problems can be addressed with the right strategy and leadership.
